• Home
  • Altruist Biologics

Altruist Biologics

About Altruist Biologics

Altruist Biologics is a reliable CDMO, focusing on the end-to-end development and commercial manufacturing of antibodies, fusion proteins, ADCs, and other drugs. From cell line development to aseptic fill/finish, we are committed to supporting our clients develop affordable and high-quality biopharmaceuticals for the benefit of patients worldwide. We offer 60KL capacity at our Suzhou site, and commenced partial operations at our new Hangzhou facility with the completion of four 20KL bioreactors, the first and largest of its kind in China. It will hold a total 172KL capacity when complete.

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • US
  • 2023
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Primary activities
Biopharmaceutical
Contract Manufacturer
Regulatory Affairs
View company profile
Contact info
  • 14695704546
  • Website
  • 9900 Belward Campus Drive, Dr Suite 300, 20850, Rockville, MD, United States
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

Products from Altruist Biologics (5)

  • BYVASDA®: Bevacizumab Injection

    Product BYVASDA®: Bevacizumab Injection

    Received NMPA marketing approval on Jun 19, 2020 Approved for advanced non-small cell lung cancer and metastatic colorectal cancer, adult recurrent glioblastoma, hepatocellular carcinoma, cervical cancer, ovarian cancer. A total of 8 indications have been approved and included in the NRDL
  • HALPRYZA®: Rituximab Injection

    Product HALPRYZA®: Rituximab Injection

    Received NMPA marketing approval on September, 2020 Approved for Diffuse large b cell lymphoma、Follicular lymphoma、Chronic lymphocytic leukemia HALPRYZA® has been approved in China for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, all of which are included in the NRDL.
  • SINTBILO® :Tafolecimab Injection

    Product SINTBILO® :Tafolecimab Injection

    In Aug 2023,SINTBILO® (tafolecimab injection) is approved by China's NMPA for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. Tafolecimab has the advantage of a longer dosing interval compare...
  • SULINNO®: Adalimumab Injection

    Product SULINNO®: Adalimumab Injection

    Received NMPA marketing approval on August, 2020 Approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, non-infectious uveitis. A total of eight approved indications have been included in the NRDL
  • TYVYT®: Sintilimab Injection

    Product TYVYT®: Sintilimab Injection

    In China, sintilimab has been approved for seven indications and included in the National Reimbursement Drug List (NRDL) for six indications. In January 2023, TYVYT® has been included in the NRDL for two additional indications including gastric cancer and esophageal cancer. TYVYT® is the first and the only...